Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNK | O75909 | 18/20 | 0.51 |
| ▸ | CDK12 | Q9NYV4 | 18/20 | 0.51 |
| ▸ | CCNT1 | O60563 | 16/20 | 0.51 |
| ▸ | CDK9 | P50750 | 16/20 | 0.51 |
| ▸ | CCNE1 | P24864 | 16/20 | 0.51 |
| ▸ | CDK2 | P24941 | 16/20 | 0.51 |
| ▸ | CDK7 | P50613 | 10/20 | 0.51 |
| ▸ | CCNH | P51946 | 10/20 | 0.51 |
| ▸ | MNAT1 | P51948 | 7/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25592734 | 0.93 | CCNK (0.51) | CCNKCDK12CCNT1CDK9CCNE1 | |
| SCHEMBL26326124 | 0.93 | CCNK (0.51) | CCNKCDK12CCNT1CDK9CCNE1 | |
| SCHEMBL25596034 | 0.93 | CCNK (0.51) | CCNKCDK12CCNT1CDK9CCNE1 | |
| SCHEMBL25599885 | 0.92 | CCNK (0.52) | CCNKCDK12CCNT1CDK9CCNE1 | |
| SCHEMBL25594182 | 0.92 | CCNK (0.51) | CCNKCDK12CCNT1CDK9CCNE1 | |
| SCHEMBL25597182 | 0.92 | CCNK (0.52) | CCNKCDK12CCNT1CDK9CCNE1 | |
| SCHEMBL25597206 | 0.92 | CCNK (0.52) | CCNKCDK12CCNT1CDK9CCNE1 | |
| SCHEMBL25594184 | 0.92 | CCNK (0.51) | CCNKCDK12CCNT1CDK9CCNE1 | |
| SCHEMBL25597199 | 0.92 | CCNK (0.52) | CCNKCDK12CCNT1CDK9CCNE1 | |
| SCHEMBL25592420 | 0.92 | CCNK (0.51) | CCNKCDK12CCNT1CDK9CCNE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295130-A1 | COMPOUND USEFUL AS CDK7 KINASE INHIBITOR AND USE THEREOF | TYK MEDICINES, INC. (CN) | 2023-09-21 | — | — | US | disclosed |
| US-20230295130-A1 | COMPOUND USEFUL AS CDK7 KINASE INHIBITOR AND USE THEREOF | TYK MEDICINES, INC. (CN) | 2023-09-21 | — | — | US | disclosed |
| EP-4186895-A1 | COMPOUND USEFUL AS CDK7 KINASE INHIBITOR AND USE THEREOF | TYK Medicines Inc. (CN) | 2023-05-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295130-A1 | COMPOUND USEFUL AS CDK7 KINASE INHIBITOR AND USE THEREOF | CDK7, CDK6, CDK9 | CCNK 15/4885CDK12 27/4885CCNT1 42/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.